<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>42-ANDROGENS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANDROGENS" code="A14AA0" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to the direct effect on coagulation and/or the fibrinolytic systems.

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Adjustment of the dosage of the Vitamin K antagonist during the treatment with the androgen and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>42-ANDROGENS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANDROGENS" code="A14AA0" /></DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the androgen and consequently of its effectiveness, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring during the administration of these substances together and 1 to 2 weeks after the inducer is stopped. </COMMENT>
</INTERACTION>
</INTERACTIONS>
